Metformin and Nightly Fasting in Women With Early Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This phase IIb trial studies the combined effect of prolonged nightly fasting and metformin
hydrochloride extended release in decreasing breast tumor cell proliferation and other
biomarkers of breast cancer. Preventing invasive breaset cancer or DCIS. Metformin is widely
used to treat type II diabetes and is associated with a decreased risk of cancer and death in
diabetic individuals. Intermittent fasting may protect cancer patients from the toxic effects
of chemotherapy agents without causing chronic weight loss. The combination of intermittent
fasting and metformin may reduce breast cancer growth and may be used in women at risk for
breast cancer or other cancers associated with being overweight.